Learn
- Review the current HF treatment gaps
- Discuss the latest evidence-based recommendations for changes to guideline-directed medical therapy (GDMT) and key changes to prior CHF guidelines
- Explore the role that technology could play in improving HF care while reducing the burden on care teams
Less than 1% of heart failure (HF) patients with reduced ejection fraction are on target doses of all four drug classes within 12 months of an index hospitalization, yet these protocols have been proven to improve symptoms, slow disease progression, reduce costly admissions, and increase life expectancy. This data point must serve as a rallying cry in the nation’s quest to combat heart failure as a leading cause of death.
Download Presentation Slides
Download the Transcript
This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. By remaining on this website you indicate your consent. For more information please visit our Privacy Policy.